<div id="readability-page-1"><div>Forus Raises $160M to Build the Foundation for Modern Medicine As biotech innovation accelerates, Forus is building the network that ensures new therapies reach every patient who needs them Forus, the company accelerating medicine for the people who need it, prescribe it, and create it, today announced it has raised over $160M. Formerly known as Tandem, the company is backed by Thrive Capital, General Catalyst, Accel, Bain Capital Ventures (BCV), Redpoint, BoxGroup, and Pear VC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512458472/en/ Scientific progress in medicine is accelerating, but getting breakthroughs to patients remains slow and unreliable. Bringing a new drug to market takes 10 to 15 years and costs $2.6 billion on average. Even after FDA approval, too many eligible patients never receive treatment – caught in a system that wasn't built for the complexity of modern medicine. Most promising drugs never make it to market, and those that do reach only a fraction of the patients who could benefit. Forus is the AI-powered network that connects doctors, pharmacies, payers, and biopharma to bring new science to patients. Embedded into physician workflows, the platform automates all steps between a clinical decision and a patient starting treatment, including insurance authorization, financial assistance, and fulfillment routing. Forus supports every drug, payer, and pharmacy in the country and is free for both doctors and patients. By abstracting away complexity, Forus gives doctors the confidence to prescribe the most effective treatments and gives patients the certainty they will receive them. “Drug discovery is moving faster, but the system that turns it into real-world treatment isn’t,” said Sahir Jaggi, CEO and founder of Forus. “We are creating that missing layer. We're grateful to the clinicians across the country who already trust Forus to get their patients on treatment. There’s an opportunity to unlock an order of magnitude more treatment options for doctors and patients, and we are building a team whose ambition matches that goal.” Forus is used by thousands of medical practices and health systems in all 50 states and is expanding rapidly across specialties. Provider adoption grew 10x year-over-year for the last two years, driven entirely by word of mouth. With that growth, Forus already supports people in nearly 80% of U.S. residential zip codes, including many patients with complex conditions who are now, for the first time, on treatment that could change the course of their disease. Forus plays an unprecedented role in moving prescriptions through the system, with unique insight into where providers get stuck, where patients drop off, and how medicines perform across populations. That perspective helps life sciences companies design better research, launch new medicines more efficiently, and invest in harder-to-treat conditions. Five of the top 10 global biopharma companies are already working with Forus. “Too often, patients miss out on the right treatment not because the therapy doesn't exist, but because the system to deliver it falls short,” said Kareem Zaki, Partner at Thrive Capital. “Forus is addressing this from first principles. By making therapies reliably accessible in practice, they can both improve outcomes today and expand what’s possible in medicine over time.” About Forus Forus accelerates medicine for the people who need it, prescribe it, and create it. The company is building a first-of-its-kind network that connects doctors, pharmacies, payers, and biopharma to bring new science to patients. The AI platform that powers this network is used by providers across all 50 states, supporting millions of patients each year. Forus is backed by leading investors including Thrive Capital, General Catalyst, and Accel. Learn more at www.forus.com. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTI0NTg0NzJyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTI0NTg0NzJyMQ"/> Forus Communications media@forus.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260512458472/en/</div></div>

美国医药设备 ETF - iShares

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

Forus 已筹集超过 1.6 亿美元，以提升现代医学的交付。该公司，前身为 Tandem，旨在通过一个基于人工智能的网络连接医生、药房、支付方和生物制药公司，简化将新疗法送达患者的过程。在 Thrive Capital 和 General Catalyst 等知名投资者的支持下，Forus 解决了当前医疗系统中的低效问题，这些问题常常导致患者延迟或无法获得必要的治疗。该平台已在所有 50 个州投入使用，支持数百万患者，并在各个医疗专业领域迅速扩展

Forus Raises $160M to Build the Foundation for Modern Medicine

MorningStar

易方达中证生物科技主题ETF

华夏中证全指医疗器械ETF

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

招商中证生物科技主题ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做空卫生保健 ETF - ProShares

华夏中证生物科技主题ETF

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技ETF基金

标普健康医疗设备 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

2 倍做空纳斯达克生物技术 ETF - ProShares

招商中证全指医疗器械ETF

医疗器械ETF永赢

General Catalyst Global Resilience Merger - Unit

Accel ENT

Bain Capital Specialty Finance

Forus 筹集了 1.6 亿美元用于构建现代医学的基础